William S. Powell

William S. Powell

Auto-generated profile, based on publicly available information

William S. Powell

Meakins-Christie Laboratories, Centre for Translational Biology, Research Institute of the McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada

Research Focus & Metrics

Academic Career Length

58Years (1969-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 April 2015 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
WPWilliam S. Powell
William S. Powell
JRJoshua Rokach
Joshua Rokach


15 September 2001 in Blood
Verified
Journal Article
Open access
GMGuillaume Monneret
Guillaume Monneret
SGSylvie Gravel
Sylvie Gravel
MDMichael Diamond
Michael Diamond
JRJoshua Rokach
Joshua Rokach
WPWilliam S. Powell
William S. Powell
Prostaglandin D2 (PGD2) is released following exposure of asthmatics to allergen and acts via the adenylyl cyclase–coupled receptor for PGD2 (DP receptor). In this study, it is reported that human eosinophils possess this receptor, which would be expected to inhibit their activation. In contrast, it was found that prostaglandin D2 is a potent stimulator of eosinophil chemotaxis, actin polymerization, CD11b expression, and L-selectin shedding. These responses are specific for eosinophils, as neutrophils display little or no response to prostaglandin D2. They were not due to interaction with receptors for other prostanoids, as prostaglandins E2 and F2α, U46619 (a thromboxane A2 analogue), and carbaprostacyclin (a prostacyclin analogue) displayed little or no activity. Furthermore, they were not shared by the selective DP receptor agonist BW245C and were not prevented by the selective DP receptor antagonist BWA868C, indicating that they were not mediated by DP receptors. In contrast, the prostaglandin D2 metabolite 13,14-dihydro-15-oxoprostaglandin D2 induced eosinophil activation but did not stimulate DP receptor–mediated adenosine 3′,5′–cyclic monophosphate (cAMP) formation. These results indicate that in addition to the classic inhibitory DP1 receptor, eosinophils possess a second, novel DP2 receptor that is associated with PGD2-induced cell activation. These 2 receptors appear to interact to regulate eosinophil responses to PGD2, as blockade of DP1 receptor–mediated cAMP production by BWA868C resulted in enhanced DP2receptor–mediated stimulation of CD11b expression. The balance between DP1 and DP2 receptors could determine the degree to which prostaglandin D2 can activate eosinophils and may play a role in eosinophil recruitment in asthma.

1 April 2014 in Immunity
Verified
Journal Article
Closed access
FCFrançois Coulombe
François Coulombe
JJJoanna Jaworska
Joanna Jaworska
MVMark Verway
Mark Verway
FTFanny Tzelepis
Fanny Tzelepis
AMAmir Massoud
Amir Massoud
MDMaziar Divangahi
Maziar Divangahi

17 April 1998 in Analytical Chemistry
Verified
Journal Article
Closed access
PTPetra Turkewitsch
Petra Turkewitsch
BWBarbara Wandelt
Barbara Wandelt
GDGraham D. Darling
Graham D. Darling
WPWilliam S. Powell
William S. Powell